Business Context and Reporting Period
This Form 8-K Current Report from Minerva Neurosciences, Inc. (Nasdaq: NERV) covers events occurring on December 22, 2025, specifically the Company's 2025 Annual Meeting of Stockholders. The filing details the election of directors, the approval of corporate governance amendments, and the ratification of the independent auditor.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial performance data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Voting Results
Stockholders approved several key proposals at the Annual Meeting. As of the record date (October 23, 2025), there were 6,993,406 shares of Common Stock and 1,391,674 shares of Series A Convertible Voting Preferred Stock outstanding (8,385,080 shares on an as-converted basis). The approved matters include:
- Director Elections: Fouzia Laghrissi-Thode and Inderjit Kaul were elected to the Board of Directors.
- Authorized Share Increase: Approval to increase authorized Common Stock from 125,000,000 to 250,000,000 shares.
- Preferred Stock Conversion: Approval for the issuance of Common Stock upon conversion of Series A Preferred Stock to comply with Nasdaq Listing Rules.
- Equity Plan Amendment: Approval to increase the aggregate number of shares authorized for issuance under the 2013 Equity Incentive Plan by 12,500,000 shares.
- Executive Compensation: Advisory approval of Named Executive Officer compensation.
- Auditor Ratification: Ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Guidance, Outlook, and Risks
The filing does not contain management commentary regarding future financial guidance, operational outlook, specific risks, contingencies, or unusual items. The document focuses strictly on the procedural outcomes of the Annual Meeting.
Investor Verification Checklist
- Verify the impact of the 12,500,000 share increase to the 2013 Equity Incentive Plan on potential future dilution.
- Review the definitive proxy statement filed on November 24, 2025, for detailed terms of the 2013 Plan amendment.
- Confirm the conversion mechanics for the Series A Convertible Voting Preferred Stock following the stockholder approval.
- Monitor the Company's upcoming financial reports for the fiscal year ending December 31, 2025, as no financial data is present in this 8-K.